 |
Journal articles
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Francisco Alves
1
Inês Antunes
2
Emiliano Cazzola
3
Frederik Cleeren
4
Bart Cornelissen
2
Antonia Denkova
5
Jonathan Engle
6
Alain Faivre-Chauvet
7
Nic Gillings
8
Jeroen Hendrikx
9
Amir Jalilian
10
Nicholas van der Meulen
11
Renata Mikolajczak
12
Oliver Neels
13
Maroor Pillai
14
Raymond Reilly
15
Sietske Rubow
16
Yann Seimbille
17
Sarah Spreckelmeyer
18
Wiktor Szymanski
19
Carlotta Taddei
20
7
CRCINA-ÉQUIPE 13 - Nuclear Oncology
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
Francisco Alves 1
Author
Inês F Antunes 2
Author
Emiliano Cazzola 3
Author
Frederik Cleeren 4
Author
Bart Cornelissen 2
Author
Antonia Denkova 5
Author
Jonathan Engle 6
Author
Alain Faivre-Chauvet 7
Author
Nic Gillings 8
Author
Jeroen J M A Hendrikx 9
Author
Amir R Jalilian 10
Author
Nicholas P van der Meulen 11
Author
Renata Mikolajczak 12
Author
Oliver C Neels 13
Author
Maroor R A Pillai 14
Author
Raymond Reilly 15
Author
Sietske Rubow 16
Author
Yann Seimbille 17
Author
Sarah Spreckelmeyer 18
Author
Wiktor Szymanski 19
Author
Carlotta Taddei 20
Author
1
UC - University of Coimbra [Portugal] (Portugal)
2
UMCG - University Medical Center Groningen [Groningen] (PO box 30.001
9700 RB Groningen - Netherlands)
4
KU Leuven - Catholic University of Leuven - Katholieke Universiteit Leuven (Oude Markt 13 - bus 5005, 3000 Leuven - Belgium)
5
TU Delft - Technische Universiteit Delft (Postbus 5 2600 AA Delft - Netherlands)
6
University of Wisconsin-Madison (Madison, WI 53706 - United States)
7
CRCINA-ÉQUIPE 13 - Nuclear Oncology (Institut de Recherche en Santé de l'Université de Nantes - 8 quai Moncousu - BP 70721 - 44007 Nantes cedex 1 - France)
- CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (8 quai de Moncousu - BP 70721 - 44007 Nantes Cedex 1 - France)
- CHU Nantes - Centre hospitalier universitaire de Nantes (1 Place Alexis-Ricordeau, 44000 Nantes - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1232 (101, rue de Tolbiac, 75013 Paris - France)
- CNRS - Centre National de la Recherche Scientifique : ERL6001 (France)
- UN - Université de Nantes (1, quai de Tourville - BP 13522 - 44035 Nantes cedex 1 - France)
- UA - Université d'Angers (Université d'Angers - 40 Rue de Rennes, BP 73532 - 49035 Angers CEDEX 01 - France)
8
Rigshospitalet [Copenhagen] (Blegdamsvej 9
2100 Copenhagen - Denmark)
- Copenhagen University Hospital (Denmark)
9
NKI - Netherlands Cancer Institute (The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands - Netherlands)
- Antoni van Leeuwenhoek Hospital (Netherlands)
10
IAEA - International Atomic Energy Agency [Vienna] (Vienna International Centre, POB 100, A-1400 Vienna - Austria)
11
PSI - Paul Scherrer Institute (Villigen PSI, CH5232 Villigen, Suisse - Switzerland)
12
POLATOM - Radioisotope Centre POLATOM [Otwock, Pologne] (Otwock - Poland)
13
HZDR - Helmholtz-Zentrum Dresden-Rossendorf (Bautzner Landstraße 400, 01328 Dresden - Germany - Germany)
15
University of Toronto (27 King's College Circle, Toronto M5S 1A1 - Canada)
16
Stellenbosch University (Stellenbosch University
Private Bag X1,
Matieland, 7602,
Stellenbosch, South Africa - South Africa)
17
Erasmus MC - Erasmus University Medical Center [Rotterdam] (Rotterdam - Netherlands)
18
Charité - UniversitätsMedizin = Charité - University Hospital [Berlin] (Charitéplatz 1,
10117 Berlin - Germany)
19
University of Groningen [Groningen] (PO Box 72 , 9700 AB Groningen - Netherlands)
20
NIH - National Institutes of Health [Bethesda] (9000 Rockville Pike, Bethesda, Maryland 20892 - United States)
Abstract : Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
Results: This commentary of highlights has resulted in 21 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. Also the first contribution in relation to MRI-agents is included.
Conclusions: Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
Document type :
Journal articles
Domain :
Complete list of metadata
https://www.hal.inserm.fr/inserm-03338402
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Wednesday, September 8, 2021 - 3:49:29 PM
Last modification on : Wednesday, January 19, 2022 - 3:44:04 PM
Long-term archiving on: : Friday, December 10, 2021 - 9:55:18 AM
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Wednesday, September 8, 2021 - 3:49:29 PM
Last modification on : Wednesday, January 19, 2022 - 3:44:04 PM
Long-term archiving on: : Friday, December 10, 2021 - 9:55:18 AM
File
FaivreChauvet2021Eq13.pdf
Publication funded by an institution
Identifiers
- HAL Id : inserm-03338402, version 1
- DOI : 10.1186/s41181-021-00146-9
- PUBMED : 34495412
Collections
INSERM | CRCINA | UNIV-NANTES | UNIV-ANGERS | CNRS
Citation
Francisco Alves, Inês Antunes, Emiliano Cazzola, Frederik Cleeren, Bart Cornelissen, et al.. Highlight selection of radiochemistry and radiopharmacy developments by editorial board. European Association of Nuclear Medicine, issuing body - EJNMMI radiopharmacy and chemistry, London : Springer Open, [2016]-, 2021, 6, pp.31. ⟨10.1186/s41181-021-00146-9⟩. ⟨inserm-03338402⟩
Metrics
Les métriques sont temporairement indisponibles